Hori Yuri, Okada Yosuke, Sonoda Satomi, Torimoto Keiichi, Tanaka Yoshiya
Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JPN.
Cureus. 2024 Sep 28;16(9):e70401. doi: 10.7759/cureus.70401. eCollection 2024 Sep.
Gilteritinib is a tyrosine kinase inhibitor (TKI) that treats acute myeloid leukemia (AML) by inhibiting FMS-like tyrosine kinase 3 (FLT3). This is a report on hypopituitarism induced by gilteritinib and its resolution following withdrawal. A 54-year-old woman was treated with gilteritinib for AML. She subsequently developed general fatigue. Blood tests showed low levels of anterior pituitary hormone. After 10 months of gilteritinib withdrawal, the levels of anterior pituitary hormones returned to normal values. When nonspecific symptoms such as fatigue in patients treated with gilteritinib are coupled with electrolyte abnormalities, a close checkup for hypopituitarism is recommended.
吉瑞替尼是一种酪氨酸激酶抑制剂（TKI），通过抑制FMS样酪氨酸激酶3（FLT3）来治疗急性髓系白血病（AML）。本文报告了吉瑞替尼诱发的垂体功能减退及其停药后的恢复情况。一名54岁女性因AML接受吉瑞替尼治疗。随后她出现全身乏力。血液检查显示垂体前叶激素水平较低。停用吉瑞替尼10个月后，垂体前叶激素水平恢复至正常范围。当接受吉瑞替尼治疗的患者出现乏力等非特异性症状并伴有电解质异常时，建议密切检查是否存在垂体功能减退。
